Protagonist Therapeutics (PTGX) closed at $132.04 on November 6, 2026, down 2.4% from the previous close, on volume of 903,395 shares (30-day average 697,780).
Data as of November 6, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
J&J posts late-stage trial win for plaque psoriasis pill in psoriatic arthritis
Seeking Alpha News (Sat, 7-Nov 10:40 AM ET)
H.C. Wainwright Remains a Buy on Protagonist Therapeutics (PTGX)
TipRanks (Fri, 6-Nov 10:07 AM ET)
Protagonist Therapeutics (PTGX) Gets a Buy from BMO Capital
TipRanks (Fri, 6-Nov 9:37 AM ET)
Barclays Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)
TipRanks (Fri, 6-Nov 4:11 AM ET)
Protagonist GAAP EPS of $3.07 beats by $0.38, revenue of $274.4M beats by $33.08M
Seeking Alpha News (Thu, 5-Nov 5:36 PM ET)
Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update
ACCESS Newswire (Thu, 5-Nov 4:11 PM ET)
Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026
ACCESS Newswire (Tue, 27-Oct 7:00 AM ET)
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
ACCESS Newswire (Tue, 8-Sep 4:05 PM ET)
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
ACCESS Newswire (Wed, 2-Sep 7:05 AM ET)
ACCESS Newswire (Fri, 28-Aug 8:30 PM ET)
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Protagonist Therapeutics trades on the NASDAQ stock market under the symbol PTGX.
As of November 9, 2026, PTGX stock price climbed to $135.47 with 147,537 million shares trading.
PTGX has a beta of 0.46, meaning it tends to be less sensitive to market movements. PTGX has a correlation of 0.02 to the broad based SPY ETF.
PTGX has a market cap of $8.77 billion. This is considered a Mid Cap stock.
Last quarter Protagonist Therapeutics reported $274 million in Revenue and $3.07 earnings per share. This beat revenue expectation by $28 million and exceeded earnings estimates by $.43.
In the last 3 years, PTGX traded as high as $160.81 and as low as $14.78.
The top ETF exchange traded funds that PTGX belongs to (by Net Assets): IJR, VTI, IWM, VB, XBI.
PTGX has outperformed the market in the last year with a return of +69.8%, while the SPY ETF gained +13.3%. However, in the most recent history, PTGX shares have underperformed the stock market with its stock returning -7.3% in the last 3 month period and -2.1% for the last 2 week period, while SPY has returned -1.9% and -1.0%, respectively.
PTGX support price is $128.25 and resistance is $135.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTGX shares will trade within this expected range on the day.
